All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
This article provides a summary of a study recently published in Blood by Amit Sud, Institute of Cancer Research, London, UK and the German Cancer Research Center, Heidelberg, DE, and colleagues. The study aimed to investigate the familial risks in hematological malignancies using a large database registry in Sweden.
Hematological malignancies differ by their clinical phenotype depending on whether the progenitor cell was of lymphoid origin or myeloid origin. Examples of malignancies of lymphoid origin include; lymphomas, B-cell and T-cell leukemias and multiple myeloma (MM), whilst the myeloid malignancies include; acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs).
Aside from some established risk factors, such as exposure to DNA-damaging agents, the etiological basis of most hematological malignancies is poorly understood. It is possible that there are inherited factors involved in this process, with some types of hematological malignancies linked to hereditary factors in recent genome-wide association studies.
A better understanding of familial risk in hematological malignancy may allow healthcare professionals to identify patients at a higher risk, and will enhance knowledge of genetic susceptibility of the disease.
Using the Swedish Family-Cancer Database of 16.1 million individuals, 153,115 patients diagnosed with a primary hematological malignancy were identified between 1958 and 2015. The authors of the study aimed to quantify the familial relative risk (FRR), which was defined as the ratio of the number of observed cases of a hematological malignancy in first-degree relatives (FDRs) of patients, to the expected number of cases in FDRs of patients. To do this, they calculated standardized incident ratios (SIR) in 391,131 FDRs to compare the risk of developing a hematological malignancy compared to the general population. Statistical analysis was conducted, and a two-sided p value of 0.05 was determined to indicate statistical significance.
The study included patients diagnosed with; all hematological malignancies, all myeloid malignancies, MPNs, AML, acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), nodular sclerosis HL (NSHL), mixed cellularity HL (MCHL), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Burkitt lymphoma (BL), small lymphocytic leukemia (SLL), hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), MM, mature T-cell lymphoma (MTCL), anaplastic T-cell lymphomas (ATCL) and cutaneous T-cell lymphoma (CTCL).
Nearly all hematological malignancies analyzed showed a statistically significant increase in the risk of a family member developing the same malignancy (Table 1).
Hematological malignancy |
Increase in FRR (-fold) |
---|---|
AML |
1.5 |
DLBCL |
2 |
FL |
2 |
MM |
2 |
CLL |
5.6 |
ET |
6.8 |
MDS |
6.9 |
PV |
7.7 |
HCL |
8.3 |
NSHL |
9.8 |
MCL |
13.3 |
LPL/WM |
15.8 |
MCHL |
16.7 |
The investigators subsequently analyzed the FRR by age at diagnosis, type of relationship, and number of affected FDRs (Table 2). In several malignancies, this demonstrated a significantly increased risk for family members of patients diagnosed at a younger age, siblings, and those with a higher number of affected FDRs.
Hematological malignancy |
SIR |
P value |
|
---|---|---|---|
Age at diagnosis (years) |
Younger |
Older |
|
HL (≤28 vs >28) |
5.76 |
3.36 |
7.3 x 10-3 |
CLL (≤63 vs >63) |
6.99 |
4.83 |
1.1 x 10-3 |
MPNs (≤59 vs >59) |
6.46 |
4.15 |
4 x 10-3 |
PV (≤59 vs >59) |
10.91 |
5.96 |
0.03 |
MDS (≤68 vs 68) |
11.95 |
3.27 |
8.8 x 10-3 |
Relationship |
Sibling |
Parent/offspring |
|
NHL |
1.97 |
1.69 |
Not available (NA) |
HL |
7.45 |
3.09 |
NA |
CLL |
7.8 |
5.36 |
NA |
AML |
3.08 |
1.09 |
NA |
LPL/WM |
5.56 |
21.88 |
NA |
Number of affected FDRs |
≥2 |
1 |
|
All |
2.08 |
1.31 |
2.1 x 10-12 |
CLL |
27.13 |
5.36 |
1.34 x 10-8 |
All myeloid |
4.55 |
1.96 |
0.02 |
All MPNs |
17.82 |
4.83 |
0.01 |
Example: in CLL, the lifetime risk for the generation population is 0.4%, so an FRR of 6.99 for a patient whose relative was diagnosed at the age of 63 or under, increases this risk to 2.2%.
This low overall lifetime risk therefore has limited clinical value.
The authors examined FRR between all hematological malignancies and found that whilst the strongest connections were disease-specific, some patterns of familial risk were identified. Most were cell-lineage specific, for example CLL had associated familial risk with nearly all B-cell tumors. Other risk associations were cross-lineage, for example HL, DLBCL, MCL, CLL and MM shared risk with myeloid malignancies.
Advantages |
Limitations |
---|---|
Large sample size |
Advances to the classification system would further refine FRR estimates |
Swedish Family Cancer Database contains near complete case registration for nearly all cases of hematological malignancies, avoiding bias |
No information available about other risk factors within families such as shared environmental risk factors that may increase FRR |
Long-term follow-up |
Potential that misclassification impacted these calculations |
|
Study may only be applicable to Western populations |
|
Limited power for malignancies recorded after 1993 |
|
The absolute risk of developing a hematological malignancy remains small, so these data are of limited clinical significance |
This study has shown significantly elevated risks in FDRs for the same malignancy, particularly in patients with relatives who were diagnosed at a younger age, or who have multiple affected FDRs. The increased FRR by age of onset may indicate that genetic predisposition is involved in disease risk.
The FRR was also found to be increased across different hematological tumors. Therefore, it may be inferred that there are shared etiological factors between these malignancies, both within the same hematopoietic lineage at different stages of differentiation, and also across lineages.
This large, retrospective, population-based analysis may help to inform future studies that investigate the etiology of hematological malignancies. It also provides the basis of a rationale to provide counselling and genetic testing to family members of patients diagnosed with a hematological malignancy, in order to accurately stratify patients by individual risk.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox